Thymosin Alpha-1 vs AOD-9604: Switching Between Them

HealthRX.com

No evidence supports switching between these two peptides

Print or save as PDF

Key numbers

  • 1.6 mgItalian Zadaxin label dose of thymosin alpha-1 per injection, given twice weeklySource: fda.gov, as cited Nov 7, 2026
  • 45.8%HBeAg loss at 72 weeks with thymosin alpha-1 plus interferon in HBeAg-positive hepatitis BSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 24-weekLength of the oral AOD-9604 human obesity study that missed its primary weight-loss endpointSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • Drug A / Thymosin alpha-1 (thymalfasin), a 28-amino-acid immune-modulating peptide
  • Drug B / AOD-9604 (hGH fragment 176-191), a 16-amino-acid growth hormone fragment
  • Shared target / None described; immune cells for one, fat tissue for the other
  • FDA approval / Neither is FDA-approved [1][2]
  • FDA compounding page / Both appear in the 'nominated but withdrawn' table with immunogenicity concerns posted [4]
  • Human evidence A / A 2026 Cochrane review found low or very low certainty evidence in chronic hepatitis B [5]
  • Human evidence B / A 24-week oral AOD-9604 obesity study failed to show a significant benefit on its primary weight-loss endpoint [3]
  • Sport / AOD-9604 prohibited at all times by WADA; thymosin alpha-1 not named [6][7]

What would a switch between these two peptides actually involve?

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide described as an immune modulator that augments T-cell function [1][8]. AOD-9604 is a modified fragment of human growth hormone: residues 177 to 191 with an extra tyrosine at the N-terminus, 16 amino acids in total, which is why it is also called hGH fragment 176-191 [9].

They are different peptides and are not interchangeable.

Thymosin alpha-1: an immune peptide with a mixed trial record

In the laboratory, thymosin alpha-1 primes dendritic cells through Toll-like receptor 9 signaling and shapes T-helper responses [10]. In healthy volunteers after subcutaneous injection it was absorbed quickly, peaking at about 0.7 to 2 hours, and cleared with a half-life of about 1.8 to 2.6 hours, with no accumulation after daily dosing for five days [1].

The human record is mostly chronic hepatitis B, and it is uneven. A 2026 Cochrane review of randomized trials found the evidence for thymosin alpha-1 in chronic hepatitis B to be low or very low certainty, and the reviewers said they were not sure it helps [5]. All-cause mortality may have been lower with thymosin alpha-1 (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people), but the certainty was very low, and the review found little to no effect on quality of life or on liver histology [5].

A double-blind trial in 98 adults with HBeAg-positive hepatitis B added thymosin alpha-1 or placebo to 24 weeks of lymphoblastoid interferon. Loss of HBeAg at 72 weeks was 45.8% versus 28.0%, a difference of 17.8% (95% CI -1.2 to 35.3) that did not reach statistical significance (P=0.067) [11]. An earlier placebo-controlled pilot in 12 people gave thymosin fraction 5 or thymosin alpha-1 to 7 and placebo to 5, and reported HBV DNA clearance in 6 of 7 treated patients versus 1 of 5 on placebo (P<0.04) [12].

Approval abroad is not FDA approval. FDA's December 2024 review found no US application and lists authorizations in Italy (adjuvant to influenza vaccination in immunocompromised people), India (chronic hepatitis B in adults 18 or older with compensated liver disease and viral replication) and Hong Kong, plus four US orphan drug designations, which are a separate process and not approvals [1]. A SciClone 2014 annual report claims approval in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, which FDA could not independently verify [1]. Two older reviews by authors tied to the developer say approval in over 35 countries (2009) or more than 30 countries (2007) [13][14].

AOD-9604: rodent fat loss and a human weight trial that failed

In obese Zucker rats, oral AOD9604 at 500 micrograms/kg daily for 19 days cut body-weight gain to 15.8 g versus 35.6 g in controls, raised fat-tissue lipolytic activity and, unlike growth hormone, did not worsen insulin sensitivity on euglycemic clamp [15]. In obese mice, 14 days of intraperitoneal injections reduced body weight and fat and raised beta-3 adrenergic receptor RNA; in mice lacking that receptor the long-term weight and lipolysis effects did not appear, and the authors concluded the lipolytic action is not mediated directly through the beta-3 receptor [16]. Preclinical work found no growth hormone receptor binding [3].

The human obesity program did not succeed. A 2026 review describes a 24-week study (534 enrolled, 502 randomized) of oral AOD9604 as an anti-obesity candidate that failed to show a significant benefit on the primary weight-loss endpoint; the review notes this rests on sponsor-reported phase 2 results rather than peer-reviewed trials, and the obesity program was later dropped [3][2]. The same review found no robust human data for visceral-fat reduction or other metabolic benefit [3].

Do they interact, and is a washout needed?

Thymosin alpha-1 is described as affecting immune cells, while AOD-9604 has been studied for effects on fat tissue [8][16]. That is a description of their mechanisms, not a safety finding. No data on giving the two together or on a washout interval for switching between them are available.

The Italian Zadaxin label calls for caution when thymosin alpha-1 is used with other immune-modulating drugs [1]. There is no approved label for AOD-9604 [2][3].

Regulatory status: unapproved in the US and flagged by FDA

Neither peptide is FDA-approved [1][2]. Compounded drugs are not FDA-approved either; FDA does not review their safety, effectiveness or quality before marketing [17].

Both sit in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks when compounded (content dated April 22, 2026). FDA's posted concerns for both include immunogenicity risk for certain routes of administration, peptide-impurity and characterization problems, and safety information it called inadequate or limited. For AOD-9604 FDA adds that it 'identified serious adverse events that may be associated with AOD-9604, though causality is not clear' [4]. Removal from the earlier safety-risk category came from the nominators withdrawing, not from a finding that either substance is safe [4].

Neither peptide is in any of the three categories on FDA's interim policy list for state-licensed pharmacies. On FDA's list for outsourcing facilities, thymosin alpha-1 sits in the third category, 'nominated without adequate support', and AOD-9604 does not appear [18][19][20].

In December 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both thymosin alpha-1 free base and acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [21]. Neither peptide is among the six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax, TB-500) in HHS's draft enforcement-discretion policy filed October 28, 2026 [22][23].

In sport, AOD-9604 and hGH 176-191 are named in WADA's S2.2.3 (growth hormone fragments) and prohibited at all times, on the 2026 List in force since January 1, 2026 and on the 2027 List [6][7]. Thymosin alpha-1 is not named on either list; WADA does name thymosin-beta-4 and TB-500, which are a different peptide [6][7].

What to watch for with each one

The Italian Zadaxin label covers 1.6 mg given subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. That label says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report over 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences described as infrequent and mild [1]. In the 2026 Cochrane review, thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1056 people; low-certainty evidence) and fewer non-serious events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [5].

For AOD-9604, FDA says it identified serious adverse events that may be associated with the substance but gives no details and states that causality is not clear [4]. A 2026 review concludes human evidence is limited and largely short-term [3], and a separate 2026 review of unapproved peptides found rigorous human safety data scarce with potential for serious harm [24].

Questions worth asking

Choose the questions you want to keep

Which one has the better evidence?

They answer different questions. Thymosin alpha-1 has randomized trials and a 2026 Cochrane review in chronic hepatitis B, with low to very low certainty results, and is authorized in a few countries [5][1]. AOD-9604 has rodent data on fat loss and one sponsor-reported human obesity trial that missed its primary weight-loss endpoint [15][16][3].

Is one of these peptides better than the other?
They do different jobs, so better depends on the goal. Thymosin alpha-1 has randomized trials in chronic hepatitis B and is approved in some countries [5][1]. AOD-9604's main human obesity study failed its primary weight-loss endpoint and the program was dropped [3].
What dose of thymosin alpha-1 is on the label?
The Italian Zadaxin label covers 1.6 mg given subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1]. There is no US-approved dose [1].
Is there an approved dose of AOD-9604?
No. There is no approved dose of AOD-9604 [3]. The 24-week human obesity trial tested an oral drug candidate and failed its primary weight-loss endpoint [3].
Is AOD-9604 GRAS or FDA-approved?
Neither. FDA's GRAS Notice Inventory contains no AOD-9604 notice [25]. The developer announced a conditional GRAS conclusion from a panel it commissioned, which was not an FDA review, and it does not cover injected or compounded drug use [25].
Does AOD-9604 raise IGF-1?
Preclinical work found no growth hormone receptor binding, and human data on IGF-1 and body composition are too limited to say more [3].
Are these peptides banned in sport?
AOD-9604 and hGH 176-191 are named in WADA's S2.2.3 for growth hormone fragments and prohibited at all times, on both the 2026 and 2027 Lists [6][7]. Thymosin alpha-1 is not named on either list, which instead names thymosin-beta-4 and TB-500 [6][7].
Show all 25 referencesHide references
  1. U.S. Food and Drug Administration.
  2. Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436-40.
  3. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
  6. World Anti-Doping Agency.
  7. World Anti-Doping Agency.
  8. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
  9. Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-8.
  10. Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-74.
  11. Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
  12. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.
  13. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
  14. Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
  15. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8.
  16. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9.
  17. U.S. Food and Drug Administration.
  18. U.S. Food and Drug Administration.
  19. U.S. Food and Drug Administration.
  20. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  21. U.S. Food and Drug Administration.
  22. Official web page.
  23. Official web page.
  24. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935.
  25. GRAS Notices.
Evidence overview for Thymosin Alpha-1 vs AOD-9604: Switching Between Them